SYSTM Wealth Solutions LLC Decreases Stake in Zoetis Inc. (NYSE:ZTS)

SYSTM Wealth Solutions LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 21,761 shares of the company’s stock after selling 2,285 shares during the quarter. SYSTM Wealth Solutions LLC’s holdings in Zoetis were worth $3,772,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Focus Financial Network Inc. ADV acquired a new position in shares of Zoetis in the 4th quarter valued at $2,159,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares during the period. Axiom Investors LLC DE increased its holdings in shares of Zoetis by 36.3% in the 4th quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock valued at $117,331,000 after acquiring an additional 158,459 shares during the period. Global Assets Advisory LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $8,831,000. Finally, Franklin Street Advisors Inc. NC increased its holdings in shares of Zoetis by 4.3% in the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock valued at $20,478,000 after acquiring an additional 5,035 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $195.74 on Wednesday. The firm has a market capitalization of $88.68 billion, a P/E ratio of 37.71, a PEG ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company’s fifty day moving average is $183.65 and its two-hundred day moving average is $174.15. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.41 EPS. Analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZTS shares. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus reissued a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research note on Tuesday, August 27th. BTIG Research boosted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.